July 5, 2011 – A new treatment option may soon be available for children with neuroblastoma according to research published in the July issue of The Journal of Nuclear Medicine. The study tested the principle that combined positron emission tomography and X-ray computed tomography (PET/CT) may be used to select children with primary refractory or relapsed high-risk neuroblastoma for treatment with a molecular radiotherapy known as 177Lu-DOTATATE. This therapeutic option was found to be viable option for children with neuroblastomas. Neuroblastoma is a cancerous tumor that develops from nerve tissue in infants and children. Accounting for six to 10 percent of all childhood cancers, it does not always follow the same pattern, with some patients regressing spontaneously and other progressing, despite aggressive therapy. The long-term survival rate for neuroblastoma is below 40 percent.

July 5, 2011 – A statement was issued by Peter W. Carmel, M.D., the president of the American Medical Association (AMA), regarding cuts to Medicare payments for diagnostic imaging.

July 5, 2011 – The first radiopharmaceutical imaging agent to help physicians evaluate patients with suspected Parkinsonian syndromes (PS), such as Parkinson’s disease (PD), has been cleared by the U.S. Food and Drug Administration (FDA). GE Healthcare’s DaTscan (Ioflupane I 123 Injection) gives physicians diagnostic capability that may lead to timely, appropriate treatments for suspected PS patients.

June 30, 2011 – Breast cancer screening with mammography results in a significant reduction in breast cancer mortality, according to long-term follow-up results of a large-scale Swedish trial. The results are published online in the journal Radiology.

June 30, 2011 — Given a growing aging population, a rise in obesity rates and an increasing demand for patient-centric medical care, there are times when healthcare professionals simply need a “radiology room on wheels.”

June 30, 2011 — During the first quarter of 2011, Biosound Esaote completed a name transition to become Esaote North America. The purpose of this transition was to emphasize the relationship with its parent company, the Esaote Group.

June 29, 2011 — Vital Images, a Toshiba Medical Systems company, released Vitrea Enterprise Suite (VES), Version 6.1. Enhancements in Version 6.1 build on the Vitrea Enterprise Suite and improve clinical workflows through advancements such as expanded integration capabilities.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now